The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeadlam Regulatory News (HEAD)

Share Price Information for Headlam (HEAD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 177.00
Bid: 175.50
Ask: 181.50
Change: 0.00 (0.00%)
Spread: 6.00 (3.419%)
Open: 177.00
High: 177.00
Low: 177.00
Prev. Close: 177.00
HEAD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of awards under Deferred Bonus Plan & PSP

18 Mar 2024 16:57

RNS Number : 3014H
Headlam Group PLC
18 March 2024
 

18 March 2024

 

Headlam Group plc

(the 'Company')

Grant of awards under Deferred Bonus Plan & Performance Share Plan

 

Performance Share Plan awards

On 18 March 2024, the Company granted awards in the form of nil-cost options over a total of 935,334 ordinary shares of 5 pence each in the Company under the Company's Performance Share Plan, (the 'PSP'), including 660,635 to the following Executive Directors:

 

 

Executive Director / PDMR

 

 

 

Role

 

Number of ordinary shares over which PSP awards granted

 

Chris Payne

 

 

Chief Executive

395,402

Adam Phillips

 

Chief Financial Officer

265,233

 

As detailed in the 2023 Annual Report and Accounts published on 18 March, vesting of the PSP awards is dependent on continued employment and the achievement of performance conditions against the following measures:

- compound growth in Earnings Per Share (70%);

- relative Total Shareholder Return performance measured against the constituents of the FTSE SmallCap Index (excluding investment trusts) (20%); and

- reduction in greenhouse gas emissions (10%).

 

The performance conditions will be measured over a three-year performance period. 

In addition, the awards are further subject to an underpin performance condition that the extent of vesting reflects the overall financial performance of the Company over the three-year performance period. When making this determination the Company's Remuneration Committee will have full discretion to ensure that the final outcome is warranted based on the performance of the Company in light of all relevant factors to ensure there have been no windfalls gains.

PSP awards granted to Executive Directors are additionally subject to a two-year holding period following the date of vesting during which a dividend equivalent will accrue in the form of additional shares to the extent the awards vest, as calculated on a re-investment basis.

The number of ordinary shares over which the awards were granted was calculated on a share price of 183.80 pence per ordinary share, being the average mid-market closing share price for the five business days prior to the grant date, as derived from the London Stock Exchange daily official list. The awards are subject to the malus and clawback provisions of the PSP.

Deferred Bonus Plan ('DBP') awards

As detailed in the Directors' Remuneration Report on page 116 of the 2023 Annual Report and Accounts, rather than defer one-third of the bonus outcome into an award over shares, the Remuneration Committee has decided to defer 100% of the Executive Director's 2023 bonus outcome into an award under the DBP.

On 18 March 2024, the Company granted nil-cost options under the DBP to the following Executive Directors:

 

Executive Director / PDMR

 

 

 

Role

 

Amount of Bonus Deferred (£)

 

Number of ordinary shares over which DBP awards granted

 

Chris Payne

 

 

Chief Executive

 

118,750

 

64,608

Adam Phillips

 

Chief Financial Officer

54,375*

 

29,583

 

* Pro-rated as Adam Phillips to reflect that he joined the Company on 20 March 2023.

The 2024 DBP awards will not vest until the second anniversary of the grant date, and are subject to a dividend equivalent in the form of shares, calculated on a re-investment basis. The number of ordinary shares over which the awards were granted was calculated based on a share price of 183.80 pence per ordinary share, being the average mid-market closing share price for the five business days prior to the grant date, as derived from the London Stock Exchange daily official list.

 

Headlam Group plc

Tel: 01675 433 000

Chris Payne, Chief Executive

Email: headlamgroup@headlam.com

Adam Phillips, Chief Financial Officer

 

Alison Hughes, General Counsel & Company Secretary

Panmure Gordon (UK) Limited (Corporate Broker)

Tel: 020 7886 2500

Tom Scrivens / Atholl Tweedie

 

Peel Hunt LLP (Corporate Broker)

 

 

Tel: 020 7418 8900

George Sellar / Finn Nugent

 

 

 

 

 

 

 

 

 

 Notification and public disclosure of transactions by persons discharging managerial

 responsibilities / persons closely associated with them.

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Chris Payne

2.

Reason for the notification

a)

Position / status

Chief Executive

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer

a)

Name

Headlam Group plc

b)

LEI

213800I4AZZUJEYX9O90

4.

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each. 

b)

Identification code

ISIN: GB0004170089

c)

Nature of the transaction

Grant of nil-cost options over Ordinary Shares under the Company's Deferred Bonus Plan

d)

Price(s) and

volume(s)

Price(s)

Volume(s)

Nil

64,608

e)

Aggregated information

- Volume

- Price

N/A

f)

Date of the transaction

18 March 2024

g)

Place of the transaction

Outside a trading venue

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Adam Phillips

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer

a)

Name

Headlam Group plc

b)

LEI

213800I4AZZUJEYX9O90

4.

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each. 

b)

Identification code

ISIN: GB0004170089

c)

Nature of the transaction

Grant of nil-cost options over Ordinary Shares under the Company's Deferred Bonus Plan

d)

Price(s) and

volume(s)

Price(s)

Volume(s)

Nil

29,583

e)

Aggregated information

- Volume

- Price

N/A

f)

Date of the transaction

18 March 2024

g)

Place of the transaction

Outside a trading venue

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Chris Payne

2.

Reason for the notification

a)

Position / status

Chief Executive

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer

a)

Name

Headlam Group plc

b)

LEI

213800I4AZZUJEYX9O90

4.

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each. 

b)

Identification code

ISIN: GB0004170089

c)

Nature of the transaction

Grant of nil-cost options over Ordinary Shares under the Company's Performance Share Plan

d)

Price(s) and

volume(s)

Price(s)

Volume(s)

Nil

395,402

e)

Aggregated information

- Volume

- Price

N/A

f)

Date of the transaction

18 March 2024

g)

Place of the transaction

Outside a trading venue

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Adam Phillips

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer

a)

Name

Headlam Group plc

b)

LEI

213800I4AZZUJEYX9O90

4.

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each. 

b)

Identification code

ISIN: GB0004170089

c)

Nature of the transaction

Grant of nil-cost options over Ordinary Shares under the Company's Performance Share Plan

d)

Price(s) and

volume(s)

Price(s)

Volume(s)

Nil

265,233

e)

Aggregated information

- Volume

- Price

N/A

f)

Date of the transaction

18 March 2024

g)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQVLFFZXLEBBZ
Date   Source Headline
9th Apr 20245:00 pmRNSEmployee Long Service Awards Scheme
21st Mar 20245:13 pmRNSDirector Declaration
18th Mar 20244:57 pmRNSGrant of awards under Deferred Bonus Plan & PSP
18th Mar 20244:53 pmRNSARA & Notice of AGM
7th Mar 20242:42 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
1st Mar 202410:01 amRNSHolding(s) in Company
28th Feb 20247:00 amRNSHolding(s) in Company
13th Feb 20242:17 pmRNSHolding(s) in Company
5th Feb 20249:40 amRNSNotice of Results
2nd Feb 202411:29 amRNSHolding(s) in Company
18th Jan 20247:00 amRNSPre-Close Update
12th Dec 20237:00 amRNSTrading Update
28th Nov 20239:31 amRNSDirector/PDMR Shareholding
9th Oct 202311:55 amRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSHolding(s) in Company
12th Sep 20234:27 pmRNSEmployee Long Service Awards Scheme
5th Sep 20237:00 amRNSHalf Year Results
14th Aug 20238:27 amRNSNotice of Results
1st Aug 20232:21 pmRNSDirector/PDMR Shareholding & Exercise of Option
27th Jul 20237:00 amRNSPre-Close Trading Update
21st Jul 20237:00 amRNSHolding(s) in Company
10th Jul 20238:47 amRNSHolding(s) in Company
10th Jul 20238:40 amRNSDirector Declaration
3rd Jul 202310:37 amRNSTotal Voting Rights
29th Jun 20235:14 pmRNSGrant of awards under the Company's PSP
29th Jun 20234:18 pmRNSExercise of options / Transfer of treasury shares
2nd Jun 20237:00 amRNSDirector/PDMR Shareholding
31st May 20239:56 amRNSHolding(s) in Company
31st May 20238:18 amRNSTotal Voting Rights
30th May 20239:56 amRNSDirector/PDMR Shareholding
26th May 20232:12 pmRNSHolding(s) in Company
25th May 202312:08 pmRNSResult of AGM
25th May 20237:00 amRNSAGM Trading Update
28th Apr 202311:01 amRNSTotal Voting Rights
24th Apr 20237:00 amRNSHolding(s) in Company
14th Apr 20234:16 pmRNSEmployee Long Service Awards Scheme
13th Apr 20234:33 pmRNSGrant of awards under Deferred Bonus Plan
31st Mar 20239:52 amRNSTotal Voting Rights
28th Mar 202311:53 amRNSDirector/PDMR Shareholding
20th Mar 20234:06 pmRNS2022 Annual Report and Notice of AGM
20th Mar 20237:00 amRNSChief Financial Officer Joins
14th Mar 20237:00 amRNSNew ‘Everyroom’ brand wins leading industry award
9th Mar 20239:00 amRNSDirector/PDMR Shareholding
8th Mar 20237:00 amRNSFinal Results
3rd Mar 20237:10 amRNSCompletion of £15 million Share Buyback Programme
3rd Mar 20237:00 amRNSTransaction in Own Shares
2nd Mar 20237:00 amRNSTransaction in Own Shares
1st Mar 20233:02 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.